Corporate Banner
Satellite Banner
Technology Networks Header
Friday, October 24, 2014
Technology Networks
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
Microscopic “Walkers” Find Their Way Across Cell Surfaces
Technology could provide a way to deliver probes or drugs to cell structures without outside guidance.
Revalesio’s Drug Shows Promise in Treating Alzheimer’s
Multiple published research studies outline the potential for RNS60 to effectively treat Alzheimer’s disease by protecting neuronal function and restoring neuronal plasticity.
Getting Metabolism Right
Analysis of 89 models of metabolic processes finds flaws in 44 of them — but suggests corrections.
Persistent Pharmacokinetic Challenges to Pediatric Drug Development
Current knowledge of rational drug dose adjustments is limited, greater effort needs to be made to determine ontogenic factors that influence ADME.
‘Tissue Chip’ to Screen Neurological Toxins
UW-Madison team are developing a faster, more affordable way to screen for neural toxins.
Promise for Treatment of Pancreatic Cancer
Ultrasound microbubbles can improve tumor absorption of cancer drugs.
Animal Testing can Mislead Drug Discovery and Development
Several blockbuster drugs would not be on the market, if scientists had relied solely on drug-uptake in animal trials, according to new research.
Marijuana Compound May Offer Treatment for AD
Extremely low levels of the compound in marijuana known as delta-9-tetrahydrocannabinol, or THC, may slow or halt the progression of Alzheimer’s disease.
New Advances in the Pre-clinical Evaluation of Hepatitis B Therapies
Imperial College London to present first public HBV Data from CN Bio in vitro liver model.
ADME of Antibody-Maytansinoid Conjugates
Continued understanding of the ADME properties of ADCs entering clinical evaluations should provide additional insight into attributes that may be necessary for clinical success.
Scroll Up
Scroll Down
Return
Physiologically Based Pharmacokinetic/Pharmacodynamic Modelling for Lead Optimisation of CNS-Active Therapeutics
Simon Thomas, Cyprotex, speaking at Screening Europe 2010
Date Posted: Wednesday, August 03, 2011
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



Cyprotex Acquires CeeTox
Auquistion broadens toxicological assay and screening capabilities to the cosmetic and personal care industry.
Thursday, January 02, 2014
Cyprotex Announces a Collaborative Research Agreement with Pfizer
The deal extends over an eighteen month period and is split into two stages with the second stage being dependent on certain milestones being achieved.
Friday, November 02, 2012
Cyprotex Launch Updated Drug-Drug Interaction Regulatory Guidance
Booklet to reflect the new FDA and EMA guidelines.
Friday, August 17, 2012
Sygnature Discovery and Cyprotex Extend Successful Strategic Alliance
The companies have announced they have entered into an extension of their highly successful partnership for a further 2 years.
Monday, December 19, 2011
Cyprotex Extends Cloe® Screen Mechanism-Based Inhibition Service to Include 4 Additional Cytochrome P450 Isoforms
New assays compliment the CYP3A4 isoform assay which was launched last year.
Friday, March 30, 2007
 
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv